TrialMedical oncology (Northwood, London, England)2022

A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.

Caroline Hamm et al.PubMed ↗Publisher ↗

No numbers read from the abstract.